Lupin announced strong Q2 FY26 results, marked by significant sales growth and improved profitability. Sales reached INR 68,314 million, a 24% increase year-over-year. EBITDA rose by 63% to INR 21,376 million, resulting in a margin of 31.3%. The company’s performance was driven by growth in key markets, including North America and India, and a focus on complex generics.
Financial Performance Highlights
Lupin reported a robust financial performance for Q2 FY26:
- Sales: Increased by 24% year-over-year to INR 68,314 million.
- EBITDA: Grew by 63% year-over-year to INR 21,376 million, with a margin of 31.3%.
- Net Income: Increased by 73% year-over-year to INR 14,779 million.
Segmental Performance
Key market performances included:
- India: Sales of INR 20,777 million, up 3% year-over-year.
- North America: Sales of INR 28,720 million, up 46% year-over-year.
- EMEA: Sales of INR 7,082 million, up 24% year-over-year.
- LATAM: Sales of INR 3,443 million, showing substantial growth of 81% year-over-year.
Key Developments
Lupin achieved several key milestones during the quarter, enhancing its product portfolio and market presence:
- Launched Liraglutide Injection (gVictoza®) and Glucagon Injection in the US.
- Received US FDA approval for Risperidone Injection 25/37.5/50mg (gRisperdal Consta®).
- Strengthened Global Specialty Ophthalmology with the acquisition of VISUfarma.
R&D and Future Outlook
Lupin continues to invest in R&D, focusing on complex generics and biosimilars. The company aims to build a strong pipeline of innovative products and expand its presence in regulated markets. Emphasis remains on achieving best-in-class quality and maintaining regulatory compliance across all manufacturing sites.
Sustainability Initiatives
Lupin achieved a new benchmark in S&P Global ESG Rating 2025, showcasing its commitment to sustainability. Several sites attained BEC 1500:2024 certification for excellence in human rights practices.
Source: BSE
